MAP Pharmaceuticals (NASDAQ:MAPP.DL)

CAPS Rating: No stars

Pharmaceutical Preparations


Player Avatar zzlangerhans (99.85) Submitted: 10/28/2011 2:00:40 PM : Underperform Start Price: $15.94 MAPP.DL Score: +10.80

MAP stock has been holding up well in advance of the Levadex PDUFA on 3/26/12. I'm just having trouble seeing how at a cap of 485M, all the good news isn't already priced into this stock. I mean, come on. Assuming Levadex gets first pass FDA approval, it's another migraine drug shown to be effective against placebo entering a crowded field of migraine-specific and nonspecific pain medications. In the real world, Levadex has to compete against triptans and opiates and Topamax and a myriad of other options for PCP's and neurologists. I'm sure that some people will end up swearing by it, happily huffing their ergot, but I'm unconvinced it will be enough to justify the current valuation.

Member Avatar ikkyu2 (99.14) Submitted: 10/28/2011 2:12:38 PM
Recs: 0

Yeah, one has to ask why Levadex is supposed to do better than Migranal, which flopped.

Featured Broker Partners